Endurant Capital Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Endurant Capital Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-20,803	Closed	-$786K	–	91
2018 Q2	$786K	Sell	20,803 -50,697	-71%	-$1.94M	0.34%	51
2018 Q1	$2.33M	Sell	71,500 -36,100	-34%	-$1.58M	0.87%	30
2017 Q4	$5.24M	Buy	107,600 +7,200	+7%	+$364K	1.6%	25
2017 Q3	$5.42M	Buy	100,400 +81,200	+423%	+$4.77M	1.64%	22
2017 Q2	$1.08M	Buy	+19,200	New	+$769K	0.3%	64
2015 Q4	–	Sell	-8,700	Closed	-$371K	–	86
2015 Q3	$371K	Buy	+8,700	New	+$420K	0.12%	71

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Endurant Capital Management's PTLA Position: Q3 2018 in Review

Endurant Capital Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2018, closing a stake of 20,803 shares — an estimated $786K sold.

Endurant Capital Management first reported a position in PTLA in Q3 2015 and held it in 6 quarters. The position peaked at $5.42M in Q3 2017. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

Endurant Capital Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Endurant Capital Management sold 20,803 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $786K.
Endurant Capital Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2015 and held it in 6 quarters.
Endurant Capital Management's Portola Pharmaceuticals, Inc. position peaked at $5.42M in Q3 2017.
197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.